Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Renovaro Biosciences (NASDAQ: RENB) has completed its merger with BioSymetrics, an AI-driven drug discovery company, on April 8, 2025. The strategic combination aims to enhance Renovaro's biomarker discovery capabilities and integrate BioSymetrics' proprietary Elion platform - an AI and machine learning engine designed for uncovering complex biological relationships.
The merger brings together Renovaro's expertise in oncology with BioSymetrics' focus on epilepsy and neurological diseases. BioSymetrics' technology includes Phenograph, a translational engine for mapping clinical signals to therapeutic targets, and advanced in vivo modeling systems. The company has established partnerships with major pharmaceutical companies including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
The combined entity aims to accelerate precision medicine development through integrated AI-powered biomarker discovery and drug development, focusing on both cancer and neurological applications.
Renovaro Biosciences (NASDAQ: RENB) ha completato la sua fusione con BioSymetrics, un'azienda di scoperta di farmaci guidata dall'IA, l'8 aprile 2025. Questa combinazione strategica mira a potenziare le capacità di scoperta di biomarcatori di Renovaro e a integrare la piattaforma proprietaria Elion di BioSymetrics - un motore di intelligenza artificiale e machine learning progettato per svelare relazioni biologiche complesse.
La fusione unisce l'expertise di Renovaro in oncologia con il focus di BioSymetrics su epilessia e malattie neurologiche. La tecnologia di BioSymetrics include Phenograph, un motore traslazionale per mappare segnali clinici a obiettivi terapeutici, e sistemi avanzati di modellazione in vivo. L'azienda ha stabilito partnership con importanti aziende farmaceutiche tra cui Janssen, Pfizer, Merck, Supernus Pharma e Deerfield Cures.
L'entità combinata mira ad accelerare lo sviluppo della medicina di precisione attraverso la scoperta di biomarcatori e lo sviluppo di farmaci integrati e potenziati dall'IA, concentrandosi sia sulle applicazioni oncologiche che neurologiche.
Renovaro Biosciences (NASDAQ: RENB) ha completado su fusión con BioSymetrics, una empresa de descubrimiento de fármacos impulsada por IA, el 8 de abril de 2025. Esta combinación estratégica tiene como objetivo mejorar las capacidades de descubrimiento de biomarcadores de Renovaro e integrar la plataforma propietaria Elion de BioSymetrics - un motor de inteligencia artificial y aprendizaje automático diseñado para descubrir relaciones biológicas complejas.
La fusión reúne la experiencia de Renovaro en oncología con el enfoque de BioSymetrics en la epilepsia y enfermedades neurológicas. La tecnología de BioSymetrics incluye Phenograph, un motor translacional para mapear señales clínicas a objetivos terapéuticos, y sistemas avanzados de modelado in vivo. La empresa ha establecido asociaciones con importantes compañías farmacéuticas, incluyendo Janssen, Pfizer, Merck, Supernus Pharma y Deerfield Cures.
La entidad combinada tiene como objetivo acelerar el desarrollo de la medicina de precisión a través del descubrimiento de biomarcadores y el desarrollo de fármacos impulsados por IA, centrándose tanto en aplicaciones oncológicas como neurológicas.
레노바로 바이오사이언스 (NASDAQ: RENB)는 2025년 4월 8일, AI 기반 약물 발견 회사인 바이오시메트릭스와의 합병을 완료했습니다. 이 전략적 결합은 레노바로의 바이오마커 발견 능력을 향상시키고, 복잡한 생물학적 관계를 밝혀내기 위해 설계된 AI 및 머신러닝 엔진인 바이오시메트릭스의 독점 엘리온 플랫폼을 통합하는 것을 목표로 하고 있습니다.
이번 합병은 레노바로의 종양학 전문성과 바이오시메트릭스의 간질 및 신경 질환에 대한 초점을 결합합니다. 바이오시메트릭스의 기술에는 임상 신호를 치료 목표로 매핑하는 변환 엔진인 Phenograph와 고급 생체 내 모델링 시스템이 포함되어 있습니다. 이 회사는 얀센, 화이자, 머크, 슈퍼너스 제약, 디어필드 큐어스 등 주요 제약사와 파트너십을 체결했습니다.
결합된 실체는 AI 기반 바이오마커 발견 및 약물 개발을 통합하여 정밀 의학 개발을 가속화하는 것을 목표로 하며, 암 및 신경학적 응용 모두에 중점을 둡니다.
Renovaro Biosciences (NASDAQ: RENB) a achevé sa fusion avec BioSymetrics, une entreprise de découverte de médicaments alimentée par l'IA, le 8 avril 2025. Cette combinaison stratégique vise à améliorer les capacités de découverte de biomarqueurs de Renovaro et à intégrer la plateforme propriétaire Elion de BioSymetrics - un moteur d'intelligence artificielle et d'apprentissage automatique conçu pour révéler des relations biologiques complexes.
La fusion réunit l'expertise de Renovaro en oncologie avec l'accent mis par BioSymetrics sur l'épilepsie et les maladies neurologiques. La technologie de BioSymetrics comprend Phenograph, un moteur de traduction pour cartographier les signaux cliniques vers des cibles thérapeutiques, ainsi que des systèmes avancés de modélisation in vivo. L'entreprise a établi des partenariats avec de grandes entreprises pharmaceutiques, dont Janssen, Pfizer, Merck, Supernus Pharma et Deerfield Cures.
L'entité combinée vise à accélérer le développement de la médecine de précision grâce à la découverte de biomarqueurs et au développement de médicaments intégrés, alimentés par l'IA, en se concentrant à la fois sur les applications oncologiques et neurologiques.
Renovaro Biosciences (NASDAQ: RENB) hat am 8. April 2025 seine Fusion mit BioSymetrics, einem KI-gestützten Unternehmen für die Arzneimittelentdeckung, abgeschlossen. Diese strategische Kombination zielt darauf ab, die Fähigkeiten von Renovaro zur Entdeckung von Biomarkern zu verbessern und die proprietäre Elion-Plattform von BioSymetrics zu integrieren - eine KI- und Maschinenlern-Engine, die entwickelt wurde, um komplexe biologische Zusammenhänge aufzudecken.
Die Fusion vereint die Expertise von Renovaro in der Onkologie mit dem Fokus von BioSymetrics auf Epilepsie und neurologische Erkrankungen. Die Technologie von BioSymetrics umfasst Phenograph, eine Übersetzungs-Engine zur Kartierung klinischer Signale auf therapeutische Ziele, sowie fortschrittliche in-vivo-Modellierungssysteme. Das Unternehmen hat Partnerschaften mit großen Pharmaunternehmen wie Janssen, Pfizer, Merck, Supernus Pharma und Deerfield Cures etabliert.
Die kombinierte Einheit zielt darauf ab, die Entwicklung der Präzisionsmedizin durch integrierte, KI-gestützte Entdeckung von Biomarkern und Arzneimittelentwicklung zu beschleunigen, mit einem Fokus sowohl auf Krebs- als auch neurologische Anwendungen.
- Integration of BioSymetrics' proprietary Elion AI platform enhances drug discovery capabilities
- Established partnerships with major pharmaceutical companies (Janssen, Pfizer, Merck)
- Expansion into neurological diseases market alongside existing oncology focus
- Access to large proprietary in vivo experimentation database
- None.
Insights
The Renovaro-BioSymetrics merger represents a significant technology integration play in the AI-driven drug discovery space. BioSymetrics brings three key technological assets: the Elion platform (core AI/ML engine), Phenograph (translational mapping system), and advanced in vivo modeling with machine vision. These complement Renovaro's existing biomarker discovery capabilities, potentially creating an end-to-end AI-powered drug development pipeline.
What stands out is BioSymetrics' validated industry partnerships with pharmaceutical giants like Pfizer, Merck, Janssen, and others. These relationships provide powerful validation of their technology stack and suggest revenue-generating collaborations that Renovaro can now leverage. The combined computational infrastructure potentially addresses a critical bottleneck in traditional drug development: connecting biomarker discovery to therapeutic validation.
From a technical perspective, the integration of these platforms could create substantial efficiency gains in target identification and validation. BioSymetrics' large proprietary database of in vivo experimentation represents a valuable training dataset that, when combined with Renovaro's oncology data repository, could enable more sophisticated AI models with cross-disciplinary applications spanning oncology and neurology.
This merger strategically positions Renovaro to address fundamental challenges in precision medicine by combining complementary capabilities across the drug discovery value chain. For this micro-cap biotech (
The expanded therapeutic focus beyond oncology into neurology (particularly epilepsy) broadens Renovaro's addressable market while leveraging a unified AI methodology. BioSymetrics' established pharma partnerships, including validation from industry leaders like Pfizer and Merck, provide potential near-term revenue opportunities and pathways to commercialization that pure discovery-stage biotechs typically lack.
Critically, this transaction diversifies Renovaro's approach to value creation beyond its existing pipeline. The combined entity can potentially monetize through multiple channels: internal therapeutic development, diagnostic platforms, and technology/data partnerships with larger pharma companies. While execution risks remain significant, the merger addresses computational and biological validation capabilities within a single organization, potentially creating a more efficient R&D engine than either company possessed independently.
Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology
LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025.
Renovaro’s merger with BioSymetrics is designed to enhance Renovaro’s data repository and biomarker discovery capabilities, as well as add in vivo validation and drug discovery to Renovaro’s AI powered biomarker and diagnostic platform.
At the core of this potential synergy is BioSymetrics’ proprietary Elion platform, a cutting-edge AI and machine learning engine that has been designed to uncover complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics’ Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enables patient stratification and drug repurposing. BioSymetrics’ advanced in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling, BioSymetrics has amassed a very large database of proprietary in vivo experimentation, with associated behavioral and morphological analysis. This integrated approach potentially hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into Renovaro’s workflow, the combined business aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development.
“This merger represents a pivotal step in our mission to diagnose cancer and advance precision medicine,” said David Weinstein, CEO of Renovaro. “By combining our expertise in oncology with BioSymetrics’ expertise in epilepsy and other neurological diseases, we believe that we are creating a powerful synergy that will enhance our ability to identify new therapeutic targets, validate diagnostics and accelerate precision drug development.”
BioSymetrics’ AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, Renovaro can now access cutting-edge computational tools that are designed to enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions in oncology and neurology.
“We are excited to join forces with Renovaro to translate cutting-edge biomarker discoveries into tangible advancements in drug development,” said Anthony Iacovone, CEO of BioSymetrics. “Our AI-driven Elion platform has the potential to significantly impact precision medicine and by aligning with Renovaro’s deep expertise in immunotherapy and oncology, we believe that we can accelerate the journey from discovery to clinical application.”
The combination of Renovaro and BioSymetrics underscores a shared commitment to harnessing AI and data-driven approaches to improve patient outcomes. Moving forward, the combined company will focus on integrating AI-powered biomarker discovery with innovative drug development, ultimately intended to bring more precise and effective treatments to patients worldwide.
For more information, visit www.renovarogroup.com and www.biosymetrics.com.
About BioSymetrics
BioSymetrics is a leading AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to identify novel therapeutics. Its proprietary Elion platform integrates large-scale biological and clinical data to drive innovation in the pharmaceutical and healthcare industries. For more information, visit www.biosymetrics.com.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development. For more information, visit www.renovarogroup.com.
Forward-Looking Statements
This press release contains statements by Renovaro Biosciences Inc. (“Renovaro”, “we”, “us”, “our” or the “Company”) that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our prospects, plans, business strategy and expected financial and operational results. You can identify these statements by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would”, ”could”, ”project”, ”plan”, “potential”, ”designed”, “seek”, “target”, variations of these terms, the negatives of such terms and similar expressions. These statements are based on certain assumptions that we have made in light of our experience in our industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. You should not rely on forward-looking statements because our actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: the success or efficacy of our pipeline, platform and fundraising; our ability to successfully integrate business that we have acquired, including BioSymetrics, or that we may acquire; our ability to achieve the benefits that we expect to realize as a result of our acquisitions, including BioSymetrics; and those other risks and uncertainties discussed in the reports we have filed with the Securities and Exchange Commission (the “SEC”), such as our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date the statements were made. We do not undertake any obligation to update forward-looking information, except to the extent required by applicable law.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com
FAQ
What strategic benefits does the RENB-BioSymetrics merger bring to Renovaro's drug discovery capabilities?
How will BioSymetrics' Phenograph technology benefit RENB's research and development?
What major pharmaceutical partnerships does BioSymetrics bring to RENB through the merger?
What therapeutic areas will RENB focus on following the BioSymetrics merger?
